Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn’s Disease: Results From the VISIBLE 2 Randomised Trial

Séverine Vermeire; Geert D’Haens; Filip Baert; Silvio Danese; Taku Kobayashi; Edward V. Loftus; Siddharth Bhatia; Christian Agboton; Maria Rosario; Chunlin Chen; Wenwen Zhang; Krisztina Kisfalvi; William J. Sandborn

doi:10.1093/ecco-jcc/jjab133

August 16, 2021Journal of Crohn s and ColitisOpen Access

Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn’s Disease: Results From the VISIBLE 2 Randomised Trial

View Full Paper

Ask AI

Bookmark

Share

Abstract

Vedolizumab SC is an effective and safe maintenance therapy in patients with CD who responded to two infusions of vedolizumab intravenous induction therapy.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Vermeire et al. (2021) studied this question.

synapsesocial.com/papers/69db2bcd5b363cdf1c83585a https://doi.org/10.1093/ecco-jcc/jjab133

View Full Paper

Ask AI

Bookmark

Share

Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn’s Disease: Results From the VISIBLE 2 Randomised Trial

Abstract

Discussion

Cite This Study

Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn’s Disease: Results From the VISIBLE 2 Randomised Trial

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from Journal of Crohn s and Colitis

Keep reading

More related papers

More from Journal of Crohn s and Colitis